rxstat › Drug prices › Varicella-zoster Virus Glycoprotein E Antigen

Varicella-zoster Virus Glycoprotein E Antigen (Shingrix) price in Canada

No current shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Varicella-zoster Virus Glycoprotein E Antigen 50 mcg/0.5ml suspension costs about $176.96 per billed unit (often a pen or vial) on public drug plan price lists in Alberta, before the pharmacy's dispensing fee. It is not a covered benefit on the public plans we track; the price shown is a list price.

Varicella-zoster Virus Glycoprotein E Antigen has no current shortage reported in Canada. It has been in shortage before; the history is below.

Price by province

Strength and formAB
50 mcg/0.5ml Suspension$176.96/unitnot covered
Plan coverageNot covered

Lowest price per unit among each province's covered products, with the brand price where it is notably higher. A dash means the province does not list it. Provinces bill some products (injectables especially) per mL and others per pen or vial, so compare prices with the same unit.

Detailed price and coverage in your province:

What you'll pay at the pharmacy

These are the prices public drug plans list for the drug itself. At the counter, pharmacies add a dispensing fee and in some provinces a markup, so paying cash costs more, and for cheap generics the fee is often more than the drug. If you have a public or private plan, your share depends on its deductible and co-pay.

Listed products by province

Alberta: 1 product
  • Shingrix 50 mcg/0.5ml Suspension · GSK
    DIN 02468425 · $176.96/unit · Not covered

Price sources: Alberta Drug Benefit List and Alberta Blue Cross price list (Nov 1, 2026). Other provinces and territories will be added as their public price lists are brought in.

Shortage status

Products affected
0 / 1
Reports on file
7

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Jul 15, 2024 · Disruption of the manufacture of the drug.
Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Jul 14, 2023 · Delay in Supply. Supply available for public programs. Supply unavailable for the private market. SHINGRIX is available to order in packages of 1
Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Oct 12, 2022 · Delay in shipping of the drug.
Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Sep 8, 2022 · Demand increase for the drug.
Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Jun 17, 2020 · High demand for the drug coupled with the variable timing of supply shipments. Re-supply is ongoing with current inventory on allocation.
Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Jun 17, 2020 · High demand for the drug coupled with the variable timing of supply shipments. Re-supply is ongoing with current inventory on allocation.
Resolved
SHINGRIX
50MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02468425 · ended Jun 6, 2018 · Demand increase for the drug.

What's happening

There are no active shortage reports for Varicella-zoster Virus Glycoprotein E Antigen. Health Canada has 7 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.

Recent changes

Common questions

How much does Varicella-zoster Virus Glycoprotein E Antigen cost in Canada?

Varicella-zoster Virus Glycoprotein E Antigen 50 mcg/0.5ml suspension costs about $176.96 per billed unit (often a pen or vial) on public drug plan price lists in Alberta, before the pharmacy's dispensing fee. It is not a covered benefit on the public plans we track; the price shown is a list price.

Is Varicella-zoster Virus Glycoprotein E Antigen covered by provincial drug plans?

On the public plans' own lists: Alberta: not covered. "Special approval" means the plan covers it only for some patients, on a request from the prescriber. "Price list" means the province publishes its price but not its coverage.

When will Varicella-zoster Virus Glycoprotein E Antigen be back in stock in Canada?

Varicella-zoster Virus Glycoprotein E Antigen has no active shortage; supply is normal per Health Canada reports.

Why is Varicella-zoster Virus Glycoprotein E Antigen in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Related drugs

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.